Patients with t-AML had a higher frequency of TP53 mutation (9% versus 4%) and a lower frequency of CEBPA mutations (5% versus 15%); however, these differences were not statistically significant (P = 0.14, and P = 0.07, respectively). This evidence concerns the gene TP53 and acute myeloid leukemia.